Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells by Townsley, Elizabeth et al.
University of Rhode Island
DigitalCommons@URI
Institute for Immunology and Informatics Faculty
Publications Institute for Immunology and Informatics (iCubed)
2015
Interaction of a dengue virus NS1-derived peptide
with the inhibitory receptor KIR3DL1 on natural
killer cells
Elizabeth Townsley
Geraldine O'Connor
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has
been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of
DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Townsley, E., O'Connor, G., Cosgrove, C., Woda, M., Co, M., Thomas, S. J., Kalayanarooj, S., Yoon, IY., Nisalak, A., Srikiatkhachorn A.,
Green, S., Stephens, H. A. F., Gostick, E., Price, D. A., Carringston, M., Alter, G., McVicar, D. W., Rothman, A. L., & Mathew, A.
(2015). Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin. Exp.
Immunol.,
Available at: http://onlinelibrary.wiley.com/doi/10.1111/cei.12722/abstract
Authors
Elizabeth Townsley, Geraldine O'Connor, Cormac Cosgrove, Marcia Woda, Mary Co, Stephen J. Thomas,
Siripen Kalayanarooj, In-Kyu Yoon, Ananda Nisalak, Anon Srikiatkhachorn, Sharone Green, Henry A. F.
Stephens, Emma Gostick, David A. Price, Mary Carrington, Galit Alter, Daniel W. McVicar, Alan L. Rothman,
and Anuja Mathew
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/76
 Interaction of a dengue virus NS1-derived peptide with the inhibitory 
receptor KIR3DL1 on natural killer cells 
Elizabeth Townsley
*, Geraldine O’Connor†, Cormac Cosgrove‡, Marcia Woda*, Mary Co*, 
Stephen J. Thomas
§
, Siripen Kalayanarooj
¶
, In-Kyu Yoon
¦
, Ananda Nisalak
¦
, Anon 
Srikiatkhachorn
*
, Sharone Green
*
, Henry A.F. Stephens
#
, Emma Gostick
††
, David A. Price
††,‡‡
,  
Mary Carrington
†,‡
, Galit Alter
‡
, Daniel W. McVicar
†
, Alan L. Rothman
§§
, Anuja Mathew
* 
 
 
Running title: Dengue KIR3DL1 interactions 
 
 
Keywords: Dengue, HLA, KIR, NK, pathogenesis 
  
 
*
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, 
Worcester, MA, USA; 
†
Cancer and Inflammation Program, Laboratory of Experimental Immunology, 
Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 
USA; 
‡
Ragon Institute at MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical 
School, Boston, MA, USA; 
§
Walter Reed Army Institute of Research, Silver Spring, MD, USA; 
¶
Queen 
Sirikit National Institute for Child Health, Bangkok, Thailand; 
¦
Department of Virology, Armed Forces 
Research Institute of Medical Sciences, Bangkok, Thailand; 
#
Centre for Nephrology and the Anthony 
Nolan Trust, Royal Free Campus, University College, London, UK; 
††
Institute of Infection and 
Immunity, Cardiff University School of Medicine, Cardiff, UK; 
‡‡
Human Immunology Section, Vaccine 
Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bethesda, MD, USA; 
§§
Institute for Immunology and Informatics, University of Rhode Island, 
Providence, RI, USA. 
 
 
Corresponding author:  Dr. Anuja Mathew  
Division of Infectious Diseases and Immunology,  
S6-862, University of Massachusetts Medical School,  
55 Lake Avenue North, Worcester, MA 01655, USA. 
E-mail: anuja.mathew@umassmed.edu 
Phone: 508-856-4182    
Fax: 508-856-4890  
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1111/cei.12722
This article is protected by copyright. All rights reserved.
2 
 
Abstract  
Killer immunoglobulin-like receptors (KIRs) interact with HLA class I ligands and play a key role in the 
regulation and activation of NK cells. The functional importance of KIR-HLA interactions has been 
demonstrated for a number of chronic viral infections, but to date only a few studies have been 
performed in the context of acute self-limited viral infections. During our investigation of CD8
+
 T cell 
responses to a conserved HLA-B57-restricted epitope derived from dengue virus (DENV) non-structural 
protein-1 (NS1), we observed substantial binding of the tetrameric complex to non-T/non-B 
lymphocytes in PBMC from a long-standing clinical cohort in Thailand. We confirmed binding of the 
NS1 tetramer to CD56
dim
 NK cells, which are known to express KIRs. Using depletion studies and KIR-
transfected cell lines, we further demonstrated that the NS1 tetramer bound the inhibitory receptor 
KIR3DL1. Phenotypic analysis of PBMC from HLA-B57
+
 subjects with acute DENV infection revealed 
marked activation of NS1 tetramer-binding NK cells around the time of defervescence in subjects with 
severe dengue disease. Collectively, our findings indicate that subsets of NK cells are activated 
relatively late in the course of acute DENV illness and reveal a possible role for specific KIR-HLA 
interactions in the modulation of disease outcomes. 
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Introduction  
Killer immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer (NK) 
cells and interact with specific human leukocyte antigen (HLA) class I ligands to transduce inhibitory or 
activating signals 
1
. One of the best characterized and highly polymorphic members of the KIR family is 
the inhibitory receptor KIR3DL1, which is present in >90% of the human population and has at least 62 
allotypes 
2
. Interactions between KIR3DL1 and the HLA-Bw4 motif act to maintain NK cell inhibition. 
However, the downregulation of major histocompatibility complex (MHC) class I molecules that often 
follows viral infection or cellular transformation alleviates NK cell inhibition via KIR3DL1, leading to 
proinflammatory cytokine release and cytolytic activity. A role for KIR3DL1 in the control of chronic 
viral infections has been proposed on the basis of associations with disease outcome in HIV-infected 
individuals 
3-8
. These studies suggest that both MHC class I and KIR genotypes may contribute to 
protection in the context of HLA-B57. Moreover, KIRs that interact with HLA-C have been linked 
epidemiologically to the development of liver disease in hepatitis C virus (HCV)-infected patients  and 
protection from HCV infection in a cohort of intravenous drug users 
9
. In contrast, the role of KIR-HLA 
interactions in acute self-limited viral infections remains largely unexplored. 
Dengue virus (DENV) is a member of the flavivirus family comprising at least four distinct 
serotypes. Transmitted by the mosquito Aedes aegypti, DENV is endemic in the tropics/subtropics and 
causes an acute febrile illness known as dengue fever (DF). However, a small percentage of individuals 
experience a more severe syndrome known as dengue hemorrhagic fever (DHF). The key features of 
DHF are plasma leakage and a bleeding tendency, which develop as the fever subsides with clearance of 
viremia
10, 11
. Although both viral and host-specific factors likely influence clinical outcome, prospective 
cohort studies have identified secondary infection with a heterologous DENV serotype as a major risk 
factor for DHF 
12
. At the mechanistic level, pre-existing antibodies 
13
, memory T cell responses 
12, 14
, 
and certain HLA genotypes 
15-18
 have all been linked with more severe dengue illness.  
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A number of reports describe associations between HLA class I genotypes and dengue disease 
severity 
15-18
. In one earlier study, extended HLA region haplotypes including TNF, lymphotoxin alpha 
(LTA) and lymphotoxin beta (LTB), together with specific combinations of class I and class II alleles, 
were strongly associated with DHF during secondary DENV infection. Various aspects of disease 
outcome after DENV exposure have also been linked to functionally-defined HLA class I supertypes 
19
, 
as well as the MHC class I-related chains A/B (MICA/B) 
20-22
. These latter proteins are upregulated in 
stressed cells and interact with NKG2D, an activating receptor on NK cells. More recently, two small 
genetic studies evaluated associations between KIR-ligand pairs and susceptibility to dengue in Gabon 
and Southern Brazil 
23, 24
. Petitdemange et al. found no evidence of a role for KIR genotypes in patients 
infected with DENV-2. In contrast, Beltrame et al. detected an association between certain KIR genes 
and their cognate HLA ligands in the context of infection with DENV-3. Differences in population 
origin and the infecting DENV serotype may explain these disparate results. Other studies have noted 
NK cell activation during acute DENV infection. In particular, Azeredo et al. linked early activation of 
NK cells with mild DENV disease 
25
, whereas Green et al. found increased frequencies of NK cells 
expressing CD69 in children who developed DHF compared to those with attenuated disease 
26
. The 
mechanisms by which NK cells contribute to immune protection and immunopathogenesis in DENV 
infection therefore require further elucidation 
27, 28
. 
We recently characterized antigen-specific CD8
+
 T cells directed against a highly conserved 
HLA-B57-restricted epitope derived from DENV non-structural protein-1 (NS1) 
29
. In the present study, 
we examined binding of the corresponding B57-NS126-34 tetramer (NS1 TET) to enriched NK cell 
populations from samples obtained prior to, during and up to 1 year after the critical phase of illness 
(around the time of defervescence) in HLA-B57
+
 subjects from a clinical cohort in Thailand. Using 
KIR3DL1
+
 healthy donor peripheral blood mononuclear cells (PBMC), we confirmed that the NS1 TET 
bound mostly to CD56
dim
 NK cells, which are known to express KIRs 
30
. We then demonstrated that the 
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NS1 TET bound KIR3DL1. To determine whether there was an association between NK cell activation 
and dengue disease severity, we analyzed PBMC from our HLA-B57
+
 cohort and found marked 
activation of NS1 TET
+
 NK-enriched cells at the critical phase of illness in patients who developed 
DHF. Our results define a specific interaction between the inhibitory receptor KIR3DL1 and a DENV-
derived CD8
+
 T cell epitope with potential relevance to the immunopathogenesis of dengue disease. 
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Results 
Binding of the NS1 TET to CD8
-
 cells in PBMC from dengue patients 
 In a study of CD8
+
 T cell responses to the HLA-B57-restricted epitope NS126-34 (HTWTEQYKF) 
29
, we observed binding of the corresponding tetrameric antigen complex (NS1 TET) to CD8
-
 cells. As 
monocytes and B cells were eliminated by our gating strategy, we speculated that the NS1 TET bound a 
subset of NK cells. Furthermore, we hypothesized that the NS1 TET bound KIR3DL1 on NK cells given 
the extensive literature describing HLA-B57-restricted HIV-derived peptide ligands for this inhibitory 
receptor 
5-7, 31, 32
. Initially, we used the NS1 TET to stain PBMC obtained at a convalescent time point 
from two HLA-B57
+
 donors in our clinical cohort. The flow cytometric gating strategy is shown in 
Supplemental Figure S1A. In parallel, we used a variant B57-Gag240-249 tetramer (TW10n TET) based on 
a CD8
+
 T cell escape sequence (TSNLQEQIGW) of the wildtype HIV-derived epitope that abrogates 
HLA-B57 binding to KIR3DL1*001 
6
. We observed substantial binding of CD8
-
 cells to the NS1 TET 
with minimal binding to the TW10n TET (Figure 1A and 1B).  
 Next, we tested PBMC obtained at multiple time points during and after acute DENV infection 
from 11 HLA-B57
+
 children, two with primary and nine with secondary DENV infection (Table 1). As 
our staining panel for clinical samples was developed to phenotype CD8
+
 T cells and did not include NK 
cell-specific markers, we first confirmed that live lymphocytes excluding monocytes, T and B cells were 
predominantly NK cells. We used convalescent samples for this purpose and found that >70% of the 
CD3
-
CD8
-
CD14
-
CD19
-
 population comprised CD56
+
 NK cells in the majority of donors (Supplemental 
Figure S1B); these cells are hereafter referred to as the “NK-enriched” population. Although a 
significant proportion of NK cells can express CD8, these were excluded from our study to ensure the 
elimination of all T cells. This was considered important because CD3 downregulation during acute 
illness complicated the identification of T cells based solely on this marker. Evaluating the frequency of 
NS1 TET
+
 CD8
-
 cells in PBMC from the HLA-B57
+
 Thai cohort, we were able to detect NS1 TET
+
 NK-
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enriched cells at all time points tested in all donors (n=10; n=5 DF, n=5 DHF) (Figure 1C). The 
frequencies of these NS1 TET
+
 NK-enriched cells varied over time (Figure 1C).  
 To confirm binding of the NS1 TET to NK cells, we used a staining panel with NK lineage-
specific markers (Figure 2A, D) to analyze KIR3DL1
+
 PBMC from healthy donors and convalescent 
PBMC from Thai cohort subjects (Figure 2B, C). A fluorescence minus one control excluding the NS1 
TET, parallel staining with the TW10n TET, and KIR3DL1 antibody labeling were used to aid gate 
placement for the accurate identification of NS1 TET
+
 NK cells. We observed NS1 TET
+
 NK cell 
populations in all donors at variable frequencies and degrees of separation. Moreover, the NS1 TET 
bound mostly to CD56
dim
 NK cells, which are known to express KIRs 
30
. Given that NK cells are highly 
heterogeneous, we next determined whether NS1 TET
+
 NK cells differed phenotypically from the total 
NK cell population. We found that NS1 TET
+
 NK cells resembled typical NK cells in that they 
expressed CD161, NKp30, NKp46, and NKG2D (Figure 2D). Thus, the NS1 TET bound archetypal 
CD56
dim
 NK cells. 
 
Binding of the NS1 TET to KIR3DL1 
 We speculated that binding of the NS1 TET to NK cells was mediated via the inhibitory receptor 
KIR3DL1. To test this possibility, we used a magnetic separation protocol to deplete PBMC of 
KIR3DL1
+
 cells and compared NS1 TET binding in parallel experiments with non-depleted PBMC 
(Figure 3A, B). We found that depletion of KIR3DL1
+
 cells reduced NS1 TET binding by 66%, 
suggesting a specific interaction between these proteins on the NK cell surface. To confirm binding of 
the NS1 TET to KIR3DL1 directly, we used distinct KIR3DL1-transfected cell lines individually 
expressing the allotypes *001, *005, and *015, which represent the three major lineages of this 
inhibitory receptor 
2
. We observed significant binding of the NS1 TET to all three KIR3DL1 allotypes in 
these experiments. As expected, HLA-B57 tetramers folded with the self-peptide LF9 (LSSPVTKSF) 
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also bound all three allotypes of KIR3DL1 (Figure 3C, D, E, F) 
33
. Moreover, pretreatment with a 
KIR3DL1-specific monoclonal antibody (DX9) blocked the binding of both tetramers to KIR3DL1 
(Figure 3C, D, E, F). Collectively, these data indicate that the NS1 TET binds KIR3DL1 on the surface 
of NK cells.   
 
Peak expression of CD38 on NS1 TET
+
 NK-enriched cells occurs around fever day 0 and correlates 
with disease severity 
 To determine whether NS1 TET
+
 and total NK cells were activated during acute infection in 
HLA-B57
+
 subjects (n=2 DF 1
0
, n=3 DF 2
0
, n=5 DHF 2
0
), we assessed the expression of CD38, CD69, 
and CD71 on NK-enriched populations in PBMC samples collected prior to, during and after the critical 
phase of DENV illness. The flow cytometric gating strategy used to identify NK-enriched populations in 
these experiments is shown in Figure 4A. Representative stainings for CD69 and CD71 expression on 
PBMC obtained at an acute and convalescent time point from a subject with DHF are shown in Figure 
4B and 4C. We found that CD69 expression was mildly elevated early in disease, but remained 
relatively high at convalescent time points in patients with DF and DHF (Figure 4D). In addition, CD69 
expression on NS1 TET
+
 NK cells in individual donors was similar to the expression of CD69 on total 
NK-enriched cells. Peak CD71 expression occurred at fever day 0 on NS1 TET
+
 and total NK cells in 
many donors, but the differences were not statistically significant between patients with DF and DHF. 
Mean CD71 expression at acute time points was significantly higher in the NS1 TET
+
 NK cell 
population compared to total NK cells (p<0.01; Figure 4E).  
 Next, we examined CD38 expression on NK-enriched cell populations in this HLA-B57
+
 cohort. 
We found that CD38 expression was highly elevated on NK cells in PBMC during acute illness, but 
decreased during early convalescence and remained present on up to 40% of NK-enriched cells 1 year 
after infection (Figure 5A). More careful examination revealed that CD38 expression clearly segregated 
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into CD38
hi 
and CD38
low
 populations on NK-enriched cells at acute time points. Figure 5B shows CD38 
expression on NK-enriched cells at fever day +1 and fever day +180 in a representative donor. 
Frequencies of CD38
low 
cells followed the same pattern as CD69 expression on NK cells, with 
elevations early during infection that remained high even during convalescence (Figure 5C). However, a 
different pattern was observed for CD38
hi
 cells in both the NS1 TET
+ 
and total NK cell populations, 
with low frequencies early during acute infection becoming elevated between fever day 0 and fever day 
+1, then returning to baseline at 1 year post-infection (Figure 5D). The peak frequency of CD38
hi
 cells 
was observed on fever days 0 and +1 for both the total NK-enriched and NS1 TET
+
 NK cell populations. 
Strikingly, very high frequencies of CD38
hi
 NS1 TET
+
 and total NK cells were observed uniquely in 
patients with DHF (p=0.0571 compared to patients with DF).  
As our original gating strategy excluded CD3
-
CD8
+
 cells in the NK-enriched population, we 
further evaluated the expression of CD38, CD69, and CD71 using an inclusive approach (Supplemental 
Figure S2). Activation levels of NK-enriched populations assessed using these markers were similar in 
the presence or absence of CD3
-
CD8
+
 cells. In addition, we used a quantitative PCR to measure viremia 
levels during early clinical illness in 9 of the 11 HLA-B57
+
 subjects. As expected, plasma virus loads 
were high in all donors prior to defervesence and dropped significantly as the fever dissipated 
(Supplemental Figure S3). However, no statistically significant correlations were detected between 
viremia levels and CD38
hi
 NK cell frequencies (data not shown).  
 
Expression of KIR3DL1 on NK cells in PBMC from the HLA-B57
+
 Thai cohort 
 To extend these findings, we examined KIR3DL1 expression on NK cells in PBMC from our 
Thai cohort using the KIR3DL1-specific antibody DX9. Expression levels of KIR3DL1 are known to 
vary between donors 
4, 30, 34
, and differential expression of inhibitory KIRs can significantly impact NK 
cell function 
35
. We found substantial frequencies of KIR3DL1
+
CD56
+
 NK cells in 9 of 9 donors tested 
Page 10 of 61Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
10 
 
(Figure 6A). The frequency of KIR3DL1 on NK cells varied from 3.5% to 15%, which is consistent with 
frequencies reported elsewhere 
34
. PBMC were not available from two subjects, but genotypic studies 
indicated that both were KIR3DL1
+
. The intensity of KIR3DL1 expression varied among donors, with 
mean fluorescence intensity (MFI) values ranging across an order of magnitude (881-7,094). However, 
the sample size was too small to draw any conclusions regarding associations between KIR3DL1 
expression, KIR3DL1 subtyping and dengue disease severity (Figure 6A and Table 1).  
Finally, we measured CD69 expression to assess NK cell activation in a limited number of 
PBMC samples obtained at fever day 0 (+/- 1 day) and fever day +180. Consistent with the results 
presented above, we found high frequencies of KIR3DL1
+
CD69
+
 NK cells during acute infection 
(Figure 6B, C). At the same time, overall KIR3DL1
+
CD56
+
 NK cell frequencies remained stable (data 
not shown). Collectively, these data indicate that NK cells are activated in HLA-B57
+
 individuals during 
the critical phase of illness. 
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Discussion 
In this study, we demonstrate binding of the NK cell-expressed inhibitory receptor KIR3DL1 to 
an HLA-B57-restricted DENV NS1-derived peptide that also serves as a CD8
+
 T cell epitope. Direct ex 
vivo staining of primary human NK cells was observed with the corresponding pMHC tetramer in 
peripheral blood samples isolated from Thai children during and after acute DENV infection. Moreover, 
NS1 TET
+
 and total NK cells were activated to express CD38 during the critical phase of DENV illness 
only in HLA-B57
+
 patients with DHF, suggesting that NK cell subsets may contribute to the 
immunopathogenesis of dengue disease. This phenotypic analysis provides the first indication of a role 
for KIR-HLA interactions in an acute self-limited viral infection and suggests that innate immune 
receptors may determine the outcome of DENV infection alongside traditional adaptive responses 
12, 14
.  
Interactions between MHC class I molecules and NK cell-expressed KIRs have been associated 
with both beneficial and detrimental outcomes in various chronic viral infections 
9
 and with the 
development of autoimmune diseases 
36
. Several studies have shown that certain KIR alleles and HLA-B 
loci strongly influence the rate of progression to AIDS in HIV-infected individuals and mechanistically 
implicate NK cells as key determinants of viremic control 
3
. The interaction between HLA-B57 and 
KIR3DL1 has been extensively studied in this context. For example, Fadda et al. showed that naturally 
occurring single amino acid escape mutations in HLA-B57-restricted HIV-derived CD8
+
 T cell epitopes 
could completely abolish KIR3DL1 binding 
6, 33
. Similarly, the interaction between B57-NS126-34 and 
KIR3DL1 may represent a novel strategy by which DENV evades NK cell-mediated immunity. 
Functional studies are in progress to address this possibility. Polyfunctional assays with HLA-B57+ NK 
sensitive targets are critical to determine whether the DENV NS1 peptide can modulate NK cell function 
and are an active area of research in the laboratory. 
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In longitudinal phenotypic analyses, we found that CD69 expression on NK-enriched cells was 
elevated early during acute infection. In contrast, CD71
+
 and CD38
hi
 NK cells were rare at this time 
point and became more prevalent later, with peak frequencies around fever day 0 in several donors. The 
emergence of abundant CD38
hi
 NK cells coincided with peak CD8
+
 T cell activation in this cohort and 
the critical period for plasma leakage and thrombocytopenia in patients with DHF 
29
. Moreover, CD38
hi
 
expression on NK-enriched cells differed substantially between patients with mild (DF) and severe 
(DHF) dengue disease. These distinct activation patterns may prelude the identification of clinically 
relevant biomarkers in acute DENV infection.  
The late activation of NK cells could be a consequence of the cytokine storm associated with 
DHF. In this scenario, NS1 TET
+
 (and therefore KIR3DL1
+
) NK cells might be driven to expand 
preferentially in HLA-B57
+
 hosts due to more efficient licensing. Alternatively, NS1 TET
+
 cells may 
represent a subset of NK cells that are restrained early in infection due to interactions between B57-
NS126-34 and KIR3DL1. As flaviviruses are known to upregulate MHC class I 
37
, we propose that the 
increased expression of HLA-B57 on target cells early in infection augments NS1 peptide presentation 
during the acute viremic phase, thus enhancing KIR3DL1 interactions and maintaining NK cell 
inhibition. As viral titers fall and MHC class I expression returns to normal during defervescence, B57-
NS126-34 levels will also wane and allow “retuned” NK cells to respond vigorously.  
Despite collection over a 15 year time period, we were only able to enroll a total of 15 HLA-
B57
+
 donors due to the low frequency of this allele in Thailand. This limitation impacted the power of 
our study and the differences in CD38
hi
 expression did not quite achieve statistical significance 
(p=0.0571). In addition, the relative rarity of HLA-B*57 may confine the clinical relevance of DENV 
NS126-34 in the Thai population. The fact that not all HLA-B57
+
 KIR3DL1
+
 individuals develop DHF 
suggests the involvement of additional regulatory loops 
38
. Given the stochastic expression of KIRs, 
different individuals will co-express different combinations of inhibitory and activating receptors within 
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the KIR3DL1
+
 NK cell subset. This constellation of receptor/ligand interactions will likely contribute to 
differential effects on NK cell function. In addition, elevated levels of cytokines known to be 
upregulated in patients with dengue will almost certainly influence the quality of NK cell and T cell 
responses. It is notable in this respect that the DENV envelope (E) protein interacts directly with the NK 
cell activating receptor NKp44 
39
. 
As with most clinical studies of dengue, the delay between initial viral infection and presentation 
to the clinic or hospital prevented a very early assessment of NK cell activation in this cohort. A rapid 
NK cell response that leads to pathogen elimination may reduce the levels of antigen available for 
presentation, thereby potentially impairing the development of memory T cell populations. Indeed, NK 
cells have been implicated in the regulation of T cell immunity during viral infections, purportedly 
acting to prevent pathological responses by attenuating T cell activation in the presence of high viral 
loads 
40-42
. In this study, we found delayed activation of NK cells in HLA-B57
+
 KIR3DL1
+
 donors, 
which could hamper the development of protective memory T cell responses to DENV. This regulatory 
activity of NK cells could explain the modest CD8
+
 T cell responses directed against this highly 
conserved NS1 epitope in secondary DENV infections 
29
.  
 In conclusion, our findings suggest that NK cell subsets play a role in the development of 
adverse immune responses associated with DHF in the context of HLA-B57. Further studies are 
warranted to identify determinative KIR-HLA interactions in other acute self-limited viral infections.  
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Materials and Methods 
Study subjects and blood samples 
The study design for patient recruitment and collection of blood samples has been reported in 
detail elsewhere 
11, 43-45
. Briefly, the enrolled subjects were Thai children aged 6 months to 15 years with 
acute febrile illnesses (<72hrs) diagnosed as DF or DHF according to WHO guidelines 
46
. Serology and 
virus isolation were used to confirm acute DENV infection, and primary and secondary infections were 
distinguished on the basis of serologic responses 
11
. For donors undergoing a secondary infection, it was 
not possible to determine the previous infecting serotype(s). Blood samples were obtained daily during 
acute illness, once during early convalescence, and at various intervals during late convalescence. 
PBMC were isolated by density gradient centrifugation, cryopreserved, and stored at 70°C. Samples 
were numbered relative to the day of defervescence (designated fever day 0). Serologic HLA class I 
typing was performed as described previously using peripheral blood from immune Thai donors at the 
Department of Transfusion Medicine, Siriraj Hospital 
15, 44
. Written informed consent was obtained from 
each subject and/or his/her parent/guardian prior to study participation. The study was approved by the 
Institutional Review Boards of the Thai Ministry of Public Health, the Office of the US Army Surgeon 
General and the University of Massachusetts Medical School (UMMS). For control purposes, PBMC 
were obtained with informed consent from healthy HLA-B57
+
 dengue-naïve volunteers aged >18 years 
under approval granted by the UMMS Institutional Review Board. 
 
Peptide-MHC tetramers 
Peptide-MHC tetramers (pMHC TETs) were either obtained from the NIAID Tetramer Core 
Facility or generated in-house as described previously 
47
. The following conjugates were used in this 
study: A2-E213-221 TET-APC, B57-LF9 TET-PE, B57-NS126-34 TET-PE, B57-NS126-34 TET-APC, B57-
TW10n TET-PE, and B57-TW10n TET-APC. 
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Flow cytometry 
 As described previously 
29
, cryopreserved PBMC from Thai subjects were thawed and washed in 
RPMI before resting in RPMI/10% FBS for 2 hours at 37°C. Cells were then washed in PBS and stained 
with 1µL of pre-diluted (1:80) LIVE/DEAD
®
 Green (Molecular Probes, Invitrogen). After washing in 
FACS buffer (PBS/2% FBS/0.1% sodium azide), cells were incubated with 0.5-2µL pMHC TET 
(1µg/µL with respect to the monomeric component) for 20 minutes at 4°C. Pre-titrated monoclonal 
antibodies specific for CD3, CD8, CD14, CD19, CD28 or CD56, CD38, CD45RA, CD57, CD69, CD71, 
and CCR7 were then added for a further 30 minutes at 4°C. Monoclonal antibodies specific for CD3, 
CD14, CD16, CD19, CD56, CD69, and KIR3DL1 were used in a separate panel to identify NK cells. 
For NS1 TET staining of PBMC from healthy individuals, 1x10
7
 cells from KIR3DL1
+
 subjects were 
washed in PBS and stained with LIVE/DEAD
®
 Green. After washing in FACS buffer, cells were 
incubated with 2µL pMHC TET or a KIR3DL1-specific monoclonal antibody for 20 minutes at 4°C. 
Pre-titrated monoclonal antibodies specific for CD3, CD14, CD16, CD19, CD56, CD161, NKp30, 
NKp46, and NKG2D were then added for a further 30 minutes at 4°C. In all experiments, cells were 
washed and fixed with BD Stabilizing Fixative™ (BD Biosciences). Data were collected using a 
FACSAria™ flow cytometer (BD Biosciences) and analyzed with FlowJo version 10 (TreeStar Inc.). 
Details of all monoclonal antibodies used in this study are presented in Supplemental Table 1. 
 
KIR3DL1
+
 NK cell depletion and NS1 tetramer staining 
 PBMC were isolated from KIR3DL1
+
 healthy subjects using standard density gradient 
centrifugation and depleted of KIR3DL1
+
 cells via magnetic bead separation (Miltenyi Biotec). 
KIR3DL1-depleted PBMC were washed in FACS buffer and incubated with NS1 TET for 50 minutes at 
4°C. After a further wash in FACS buffer, cells were fixed with 100µL of pre-diluted (1:4) BD Cytofix 
Page 16 of 61Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
16 
 
(BD Biosciences) and kept at 4°C until acquisition. Flow cytometric data were collected and analyzed as 
described above. 
 
Binding of pMHC tetramers to KIR3DL1-transfected cell lines 
 Detailed analyses of KIR3DL1-transfected lines were performed as reported elsewhere 
33
. 
Briefly, HEK 293 cells were transfected with FLAG-tagged constructs of KIR3DL1*001, *005, or *015. 
An anti-FLAG monoclonal antibody was used to verify KIR3DL1 expression. Transfected cells were 
pre-incubated with 10µg/µL of the blocking monoclonal antibody DX9 or control IgG, then stained with 
0.25µL of the NS1 TET or the well described LF9 TET, representing a self-derived peptide complexed 
with HLA-B57 that binds KIR3DL1 
48
.  
 
Statistical analysis  
Comparisons between groups were conducted using the Mann-Whitney rank sum test for non-
normally distributed variables. All statistical analyses were performed using GraphPad Prism (GraphPad 
Software). 
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Abbreviations 
 
DENV    Dengue virus    
DF    Dengue fever  
DHF    Dengue hemorrhagic fever 
KIR   Killer immunoglobulin-like receptor  
LTA    Lymphotoxin alpha  
LTB    Lymphotoxin beta 
MICA/B    MHC class I-related chains A/B 
NS1   Non-structural protein-1   
NS1 TET    B57-NS126-34 tetramer  
pMHC TETs   Peptide-MHC tetramers  
TW10n TET   B57-Gag240-249 tetramer   
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Figure Legends 
Figure 1: Binding of the NS1 TET to non-CD8 cells in PBMC from Thai children with dengue. (A, 
B) Using flow cytometry, frequencies of NS1 TET
+
 (A) and TW10n TET
+
 (B) CD3
-
CD8
-
CD14
-
CD19
-
 
(NK-enriched) cells in PBMC from donors CHD01-018 and KPP94-041 at the 1 year time point. (C) 
Kinetics of NS1 TET
+
 frequencies among NK-enriched cells during acute dengue illness and 
convalescence. Fever day 0 indicates the day of defervescence. Symbols distinguish subjects with 
primary (n=2, grey symbols) versus secondary (n=8, black symbols) DENV infections and lines 
distinguish those with DF (n=5, black line) versus DHF (n=5, dashed line). 
 
Figure 2: Frequencies and phenotype of NS1
 
TET
+
 NK cells. (A) Gating strategy to identify CD56
+
 
and/or CD16
+
 NK cells. (B) Frequencies of NS1 TET
+
 NK cells in PBMC from healthy KIR3DL1
+
 
donors. Representative flow cytometry plots from 4 of 13 donors are shown on the top row. 
Fluorescence minus one (FMO), NS1 TET
+
 and TW10n TET
+
 NK cell frequencies in PBMC from 
healthy donor LD093 are shown on the bottom row. (C) Frequencies of NS1 TET
+
 NK cells in PBMC 
obtained from Thai study subjects 2 to 3 years after DENV infection. (D) Overlay of NS1 TET
+
 NK cells 
(red dots) on the total NK cell population (zebra plot) in PBMC from a healthy KIR3DL1
+
 donor. The 
expression pattern of CD161, NKp30, NKp46, and NKG2D was compared between NS1 TET
+
 NK cells 
and the total NK cell population. 
 
Figure 3: Binding of the NS1 TET to KIR3DL1. Using flow cytometry, (A, B) Frequency of NS1 
TET
+
 NK cells in PBMC from a KIR3DL1
+
 donor before (A) and after (B) magnetic depletion of 
KIR3DL1
+
 cells. Data represent one of three independent experiments. (C-F) HEK 293 cells were 
transfected with KIR3DL1 and stained with the NS1 TET (black) or the LF9 TET (grey). Histograms 
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show NS1 TET and LF9 TET binding (solid lines) to untransfected cells (C) or cells stably transfected 
with KIR3DL1*001 (D), KIR3DL1*005 (E), or KIR3DL1*015 (F). Binding of the NS1 TET and the 
LF9 TET in the presence of a monoclonal KIR3DL1-specific blocking antibody (DX9) is shown (dashed 
lines). 
 
Figure 4: Activation of NS1 TET
+
 and total NK cells over the course of acute dengue illness. (A) 
Gating strategy to identify NK-enriched cells in PBMC from Thai subjects. (B) Representative flow 
cytometry plot depicting CD69 expression on NK-enriched cells at fever day -1 and fever day +6 from a 
subject with DHF. (C) Representative flow cytometry plot depicting CD71 expression on NK-enriched 
cells at fever day 0 and fever day +180 from a subject with DF. (D, E) Kinetics of CD69 (D) and CD71 
(E) expression on NS1 TET
+
 and total NK cells during acute dengue illness and convalescence. The 
average frequencies of CD69
+
 and CD71
+
 total NK-enriched cells are shown using a solid red line for 
subjects with DF and a dashed red line for subjects with DHF. Symbols distinguish subjects with 
primary (n=2, grey symbols) versus secondary (n=8, black symbols) DENV infections and lines 
distinguish those with DF (n=5, black line) versus DHF (n=5, dashed line). 
 
Figure 5: CD38 expression on NS1 TET
+
 and total NK cells over the course of acute dengue illness. 
(A) Kinetics of CD38 expression on NS1 TET
+
 and total NK cells during acute dengue illness and 
convalescence. (B) Representative flow cytometry plots depicting CD38
hi
 versus CD38
low
 NK cell 
populations at fever day +1 and fever day +180 from a subject with DF. (C, D) Frequencies of CD38
low
 
(C) and CD38
hi
 (D) NK cell populations during acute dengue illness and convalescence. The average 
frequencies of CD38
hi
 and CD38
low
 total NK-enriched cells are shown using a solid red line for subjects 
with DF and a dashed red line for subjects with DHF. Symbols distinguish subjects with primary (n=2, 
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grey symbols) versus secondary (n=8, black symbols) DENV infections and lines distinguish those with 
DF (n=5, black line) versus DHF (n=5, dashed line). 
 
Figure 6: KIR3DL1 staining of NK cells in PBMC from Thai study cohort subjects. (A) 
Frequencies of KIR3DL1
+
 NK cells in PBMC obtained from Thai study subjects 2 to 3 years after 
DENV infection. PBMC were gated on CD56
+
 and/or CD16
+
 NK cells. Dot plots show CD56 versus 
KIR3DL1 staining. (B) Representative flow cytometry plots depicting CD69 versus KIR3DL1 
expression on NK cell populations at fever day 0 and fever day +180 from a subject with DHF. (C) 
Frequencies of KIR3DL1
+
CD69
+
 NK cell populations (n=9) during acute dengue illness and 
convalescence. 
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TABLE 1: Clinical, virological and immunogenetic profiles of HLA-B57
+
 Thai study subjects 
 
a 
Primary (P) versus secondary (S) infection as determined by IgM/IgG ratios 
11
.  
b 
Of current infection. Unknown = could not be determined. 
c
According to WHO guidelines 1997; DF = dengue fever; DHF = dengue hemorrhagic fever (grades 1-
3). 
d
 KIR3DL1 subtyping.  
 
Donor  Serologya Serotypeb  Diagnosisc  KIR3DL1d KIR3DS1 
CHD95-039 P DENV-1  DF  01502 + 
CHD06-029  P DENV-3  DF  01502, 01502 - 
CHD05-023  S DENV-1  DF  01502 + 
CHD01-018  S DENV-2  DF  020 + 
KPP94-037  S DENV-2  DF  01502,01502 - 
KPP94-041  S DENV-1  DHF-3  00501 - 
CHD02-073 S DENV-1  DHF  00501 
 
- 
CHD01-058  S DENV-2  DHF-1  01502 + 
CHD01-050  S DENV-2  DHF-3  01502 - 
CHD00-054  S unknown  DHF-2  00701 + 
CHD06-092 S DENV-4  DHF-2  00701,01502 + 
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Supplemental Figure S1. Frequencies of NK cells in the CD3-CD8-CD14-CD19- gate. 
(A) Gating strategy to identify CD3-CD8-CD14-CD19- cells. Cells were first selected 
within the lymphocyte gate as defined by forward and side scatter profiles. Singlets 
were then identified and live CD3-CD14-CD19- cells were selected in a dump 
(LIVE/DEAD® Green with αCD14 and αCD19) versus CD3 bivariate plot. CD8- cells 
were gated within this population. (B) Frequencies of CD56+ and/or CD16+ NK cells in 
PBMCs collected from Thai cohort subjects 2 years after acute DENV infection. Plots 
are gated on live CD3-CD8-CD14-CD19- cells. 
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Supplemental Figure S2. Activation of NS1 TET+ and total NK cells over the course of 
acute dengue illness. Kinetics of CD69 (A), CD71 (B), total CD38 (C), CD38low (D), and 
CD38hi (E) expression on NS1 TET+ and total NK cells during acute dengue illness and 
convalescence. The average frequencies of CD69+, CD71+, total CD38+, CD38low, and 
CD38hi total NK-enriched cells are shown using a solid red line for subjects with DF and 
a dashed red line for subjects with DHF. Symbols distinguish subjects with primary (n=2, 
grey symbols) versus secondary (n=8, black symbols) DENV infections and lines
distinguish those with DF (n=5, black line) versus DHF (n=5, dashed line). 
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Supplemental Figure S3. Magnitude of DENV viremia by day of illness. Levels of 
DENV genome equivalent (GE) cDNA (copies/mL) were determined in serial plasma 
samples from HLA-B57+ patients. Symbols denote individual subjects and lines
distinguish those with DF (n=4, black line) versus DHF (n=5, dashed line). 
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SUPPLEMENTAL TABLE 1: Antibodies used for flow cytometry studies 
Marker Clone Manufacturer Fluorochrome 
CD3 UCHT1 
OKT3 
BD Biosciences 
BioLegend 
BioLegend 
V500 
BV510 
BV510 
CD8 SK1 Invitrogen PE-AlexaFluor610 
CD45RA HI100 BD Pharmingen APC-H7 
CCR7 150503 BD Horizon V450 
CD69 CH/4 
FN50 
Invitrogen 
BioLegend 
PE-Cy5.5  
BV650 
CD38 HB7 eBioscience eFluor®650NC 
CD57 HCD57 BioLegend PerCP/Cy5.5 (Lightening Link) 
CD71 OKT9 
CY1G4 
eBioscience 
BioLegend 
PE-Cy7 (Lightening Link) 
APC 
CD28 CD28.2 BioLegend AlexaFluor700 
CD56 B159 BD Biosciences AlexaFluor700 
CD19 HIB19 BD Biosciences FITC 
CD14 HCD14 BioLegend FITC 
CD56 HCD56 BioLegend BV711 
CD16 3G8 BD Horizon APC-H7 
NKp30 P30-15 BioLegend APC 
NKp46 9E2 BioLegend BV421 
CD161 HP-3G10 BioLegend BV605 
NKG2D 1D11 BD Biosciences PE-CF594 
KIR3DL1 DX9 Beckman Coulter 
BioLegend 
PE 
PE 
KIR3DL1/S1 Z27 Beckman Coulter APC 
HLA-A,B,C W6/32 BD Biosciences 
BioLegend 
APC, PE, FITC 
PE 
HLA-B57 BIH0243 One Lambda PE-NeutrAvidin     
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